Covid-19 vaccine: First 'milestone' vaccine offers 90% protection
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Friday
August 19, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
FRIDAY, AUGUST 19, 2022
Covid-19 vaccine: First 'milestone' vaccine offers 90% protection

Coronavirus chronicle

Reuters
09 November, 2020, 06:50 pm
Last modified: 09 November, 2020, 11:36 pm

Related News

  • First lady Dr Jill Biden tests positive for Covid-19
  • Hacker offers to sell data of 48.5 mln users of Shanghai's Covid app
  • Delhi to enforce mask mandate again after spurt in Covid cases
  • US CDC no longer recommends students quarantine for Covid-19 exposure
  • Flush with wins, finally Covid-free, Biden to hit the road ahead of US midterms

Covid-19 vaccine: First 'milestone' vaccine offers 90% protection

“Today is a great day for science and humanity,” Albert Bourla, Pfizer’s chairman and chief executive, said

Reuters
09 November, 2020, 06:50 pm
Last modified: 09 November, 2020, 11:36 pm

Pfizer Inc PFE.N said on Monday its experimental Covid-19 vaccine was more than 90% effective, a major victory in the fight against a pandemic that has killed more than a million people, battered the world's economy and upended daily life.

Pfizer and German partner BioNTech SE BNTX.O are the first drugmakers to release successful data from a large-scale clinical trial of a coronavirus vaccine. The companies said they have so far found no serious safety concerns and expect to seek US authorization this month for emergency use of the vaccine.

If authorized, the number of doses will initially be limited and many questions remain, including how long the vaccine will provide protection. However, the news provides hope that other Covid-19 vaccines in development may also prove effective.

"Today is a great day for science and humanity," Albert Bourla, Pfizer's chairman and chief executive, said.

"We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen."

Biden welcomes Pfizer coronavirus vaccine news, says safety measures still needed

Pfizer expects to seek broad US authorization for emergency use of the vaccine for people aged 16 to 85. To do so, it will need two months of safety data from about half the study's 44,000 participants, which his expected late this month.

The MSCI index of world stock markets hit a record high following the announcement. Pfizer shares were indicated 6% higher in New York, while BioNTech's US stock leapt 18%.

Shares of other Covid-19 vaccine developers that are in the final stage of testing also reacted with AstraZeneca AZN.L rising 0.5% in London while Johnson & Johnson JNJ.N gained 2.6% in pre-market trading and Moderna MRNA.O down 1.8% ahead of the US bell.

"I'm near ecstatic," Bill Gruber, one of Pfizer's top vaccine scientists, said in an interview. "This is a great day for public health and for the potential to get us all out of the circumstances we're now in."

1.3 BILLION DOSES

Russia's Sputnik V vaccine over 90% effective: health ministry

Pfizer and BioNTech have a $1.95 billion contract with the US government to deliver 100 million vaccine doses beginning this year. They have also reached supply agreements with the European Union, the United Kingdom, Canada and Japan.

To save time, the companies began manufacturing the vaccine before they knew whether it would be effective. They now expect to produce up to 50 million doses, or enough to protect 25 million people this year.

Pfizer said it expects to produce up to 1.3 billion doses of the vaccine in 2021.

The US pharmaceutical giant said the interim analysis was conducted after 94 participants in the trial developed Covid-19, examining how many of them had received the vaccine versus a placebo.

The company did not break down exactly how many of those who fell ill received the vaccine. Still, over 90% effectiveness implies that no more than 8 of the 94 people who caught Covid-19 had been given the vaccine, which was administered in two shots about three weeks apart.

The efficacy rate is well above the 50% effectiveness required by the US Food and Drug Administration for a coronavirus vaccine.

To confirm the efficacy rate, Pfizer said it would continue the trial until there are 164 Covid-19 cases among participants. Given the recent spike in US infection rates, that number could be reached by early December, Gruber said.

The data have yet to be peer-reviewed or published in a medical journal. Pfizer said it would do so once it has results from the entire trial.

GLOBAL RACE

The global race for a vaccine has seen wealthier countries forge multibillion-dollar supply deals with drugmakers like Pfizer, AstraZeneca Plc and Johnson & Johnson, raising questions over when middle income and poorer nations will get access to inoculations.

The US quest for a vaccine has been the Trump administration's central response to the pandemic. The United States has the world's highest known number of Covid-19 cases and deaths with more than 10 million infections and over 237,000 fatalities.

President Donald Trump repeatedly assured the public that his administration would likely identify a successful vaccine in time for the presidential election, held last Tuesday. On Saturday, Democratic rival Joe Biden was declared the winner.

Vaccines are seen as essential tools to help end the health crisis that has shuttered businesses and left millions out of work. Millions of children whose schools were closed in March remain in remote learning programs.

Dozens of drugmakers and research groups around the globe have been racing to develop vaccines against Covid-19, which on Sunday exceeded 50 million infections since the new coronavirus first emerged late last year in China.

The Pfizer and BioNTech vaccine uses messenger RNA (mRNA) technology, which relies on synthetic genes that can be generated and manufactured in weeks, and produced at scale more rapidly than conventional vaccines.

Moderna Inc, whose vaccine candidate employs similar technology, is expected to report results from its large-scale trial later this month.

The mRNA technology is designed to trigger an immune response without using pathogens, such as actual virus particles.

Pfizer alone will not have the capacity to immediately provide enough vaccines for the United States. The Trump administration has said it will have enough supply for all of the 330 million US residents who wish to be vaccinated by the middle of 2021.

The US government has said the vaccines will be provided free to Americans, including the insured, uninsured and those in government health programs such as Medicare.

Top News

Pfizer / BionTech / 90% effective / COVID-19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • The curious case of RMG import growth overtaking export’s
    The curious case of RMG import growth overtaking export’s
  • Japanese ambassador seeks equal incentives for foreign cos at EPZs
    Japanese ambassador seeks equal incentives for foreign cos at EPZs
  • Countries heavily reliant on imported grain are already facing acute food insecurity. Photo: Reuters.
    No major food shortage in Bangladesh: World Bank

MOST VIEWED

  • People walk at a subway station, following the outbreak of the coronavirus disease (Covid-19), in Shanghai, China May 11, 2021. REUTERS/Aly Song
    Two Covid scares cause mayhem in Shanghai
  • File Photo: A woman holds a small bottle labeled with a "Vaccine Covid-19" sticker and a medical syringe in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration
    Variant-adapted Covid vaccine wins first approval in Britain
  • Southern hemisphere to get first mRNA vaccine facility
    Southern hemisphere to get first mRNA vaccine facility
  • North Korea's leader Kim Jong Un greets health workers and scientists struggling with the coronavirus disease (Covid-19) pandemic during a photo session in Pyongyang, North Korea, in this undated photo released on August 10, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS
    North Korea lifts mask mandate, distancing rules after declaring Covid victory
  • A motorist passes by a mural of frontline workers against coronavirus at RK Puram in New Delhi on July 25. Delhi’s Covid-19 recoveries have outstripped new cases on almost all days this month barring a few exceptions, after ramped-up containment and testing efforts over the past month or so. (Sanchit Khanna / HT Photo)
    Delhi to enforce mask mandate again after spurt in Covid cases
  • A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell
    US CDC no longer recommends students quarantine for Covid-19 exposure

Related News

  • First lady Dr Jill Biden tests positive for Covid-19
  • Hacker offers to sell data of 48.5 mln users of Shanghai's Covid app
  • Delhi to enforce mask mandate again after spurt in Covid cases
  • US CDC no longer recommends students quarantine for Covid-19 exposure
  • Flush with wins, finally Covid-free, Biden to hit the road ahead of US midterms

Features

We will be facing massive, recurring challenges in the coming years no matter what. Photo: Reuters

Holes in the recession story

13h | Panorama
Illustration: Bloomberg

What nonmonogamy can teach moonlighters and job jugglers

12h | Pursuit
The members of BracU Dichari in Poland for the ERL Championship Round. Photo: Courtesy

BracU Dichari: A Bangladeshi robotics team on the world stage

14h | Pursuit
FundedNext aims to provide funds to traders with the best possible trading experience and to maximise the opportunity to unleash their true potential. Photo: Noor-A-Alam

FundedNext: A global prop-trading firm built by a Bangladeshi youth

14h | Panorama

More Videos from TBS

Love, marriage, trolls, and an unusual death

Love, marriage, trolls, and an unusual death

3h | Videos
Are elephants on the verge of extinction in Bangladesh?

Are elephants on the verge of extinction in Bangladesh?

4h | Videos
BM Depot fire: Uncertainty grips RMG exporters over payment for burnt goods

BM Depot fire: Uncertainty grips RMG exporters over payment for burnt goods

6h | Videos
Eight more banks make unusual gains from forex dealings

Eight more banks make unusual gains from forex dealings

7h | Videos

Most Read

1
From left Afzal Karim, Murshedul Kabir and Mohammad Jahangir
Banking

Sonali, Agrani and Rupali banks get new MDs

2
Russia now offers Bangladesh finished oil
Energy

Russia now offers Bangladesh finished oil

3
Photo: TBS
Bangladesh

5 crushed to death as BRT girder falls on car in Uttara

4
Photo: Collected
Economy

Bangladesh is not in a crisis situation: IMF

5
Dollar price drops by Tk8 in kerb market
Economy

Dollar price drops by Tk8 in kerb market

6
Eight more banks make unusual gains from forex dealings
Banking

Eight more banks make unusual gains from forex dealings

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]